News
This was the stock's third consecutive day of gains.
Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...
17h
Zacks Investment Research on MSNVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
1d
Zacks Investment Research on MSNVertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key FactsVertex Pharmaceuticals (VRTX) closed the most recent trading day at $452.16, moving +1.56% from the previous trading session. This change outpaced the S&P 500's 0.11% loss on the day. Meanwhile, the ...
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...
What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the ...
Collin Morikawa, ranked 5th in the world, is seeking his first PGA Tour victory since October 2023 at the Rocket Classic in ...
TUESDAY, June 24, 2025 (HealthDay News) — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 ...
One-year data suggest allogeneic stem cell-derived islet-cell therapy could become a future option for those with type 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results